Drug class
Calcitonin gene-related peptide (CGRP) ligand inhibitor; humanised monoclonal antibody
Mechanism of action
Binds CGRP ligand and prevents it from activating its receptor, reducing CGRP-mediated nociceptive and vasodilatory signalling involved in migraine and cluster headache.
General use cases
- Preventive treatment of migraine in adults
- Treatment of episodic cluster headache in adults under the US product indication; not indicated for acute migraine treatment
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
